A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Inclusion Criteria:

1. Signed and dated written informed consent in accordance with ICH-GCP and locallegislation prior to admission to the trial

2. Of legal adult age (according to local legislation) at screening

3. Male or female patients. Women of childbearing potential (WOCBP) and men able tofather a child must be willing and able to use highly effective methods of birthcontrol per ICH M3 (R2) that result in a low failure rate of less than 1% per yearwhen used consistently and correctly.

4. Histologically or cytologically confirmed Pancreatic ductal adenocarcinoma (PDAC)

5. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

6. Life expectancy ≥3 months in the opinion of the investigator

7. Archived tumor tissue from a tissue core biopsy (e.g. paraffin-embeddedformalin-fixed tissue blocks), OR fresh tumor tissue available for retrospectivebiomarker analysis; in both cases, a minimum of at least two core needle biopsies (18 gauge or greater) is required. Only non-significant risk procedures per theinvestigator's judgment will be used to obtain any biopsies specified in this studyin cases where a fresh tumor biopsy is required.

8. Patients with at least 1 target lesion that can be accurately measured per RECISTversion 1.1 Further inclusion criteria apply.

Exclusion Criteria:

1. Previous exposure to trial drug (BI 765883)

2. Any prior gemcitabine and/or paclitaxel therapy (for combination therapy cohorts)

3. Known hypersensitivity to the study medications or their excipients (includinggemcitabine and nab-paclitaxel)

4. Any contraindications to gemcitabine or nab-paclitaxel according to the currentapproved local labels (combination therapy)

5. Currently enrolled in another investigational device or drug trial, or less than 28days since ending another investigational device or drug trial(s) or receiving otherinvestigational treatment(s)

6. Any serious concomitant disease or medical condition affecting compliance with trialrequirements or which are considered relevant for the evaluation of the efficacy orsafety of the trial drug, such as neurologic, psychiatric, infectious disease,active ulcers (gastrointestinal tract, skin), inflammatory bowel disease or bowelinfection, or laboratory abnormality that may increase the risk associated withtrial participation or trial drug administration, and in the judgment of theInvestigator, would make the patient inappropriate for entry into the trial.

7. Prior radiotherapy or systemic therapy within 14 days prior to treatment start

8. History or presence of cardiovascular abnormalities such as uncontrolledhypertension, congestive heart failure NYHA classification of ≥III or IV, unstableangina or poorly controlled arrhythmia which are considered as clinically relevantby the Investigator Further exclusion criteria apply.